Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mario Cala

Podiatrist, Foot & Ankle Surgery Hialeah, FL Doctor of Podiatric Medicine

NPI 1316234024 CMS profile 105336

4410 W 16Th Ave Ste 49, Hialeah, FL 33012

Open in the dashboard

General payments

$540,990

717 records reported · program years 2019–2025

Research payments

$330

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,500 paid to institutions, not to them · program years 2022–2023

Through program year 2025, Mario Cala of Hialeah, FL is reported in the CMS Open Payments database as having received $540,990 across 717 general payments and $330 in research payments paid to them. Separately, studies naming them as principal investigator received $3,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103,315 115
2024 General $107,804 115
2023 General $64,510 124
2022 General $119,382 156
2021 General $65,310 67
2020 General $6,330 33
2019 General $74,339 107
2019 Research $330 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mario Cala
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Mario Cala were reported at $103,315. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Mario Cala Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $74,339 $389 $118–$1,406 $163
2020 $6,330 $191 $62–$691 $114
2021 $65,310 $329 $104–$1,341 $132
2022 $119,382 $419 $125–$1,611 $149
2023 $64,510 $377 $128–$1,164 $160
2024 $107,804 $394 $134–$1,168 $164
2025 $103,315 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $323,358 346 payments
  2. Vilex in Tennessee, Inc. $113,785 92 payments
  3. Wright Medical Technology, Inc. $72,783 72 payments
  4. Organogenesis Inc. $12,969 35 payments
  5. Musculoskeletal Transplant Foundation Inc. $2,959 5 payments
  6. Kerecis Limited $2,837 9 payments
  7. Medical Device Business Services, Inc. $2,380 1 payment
  8. Smith+Nephew, Inc. $2,228 53 payments
  9. Misonix Inc $1,855 6 payments
  10. Sanara MedTech Inc. $1,071 8 payments
  11. Other $4,765 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $354,634 83 payments
  2. Royalty or License $62,563 32 payments
  3. Travel and Lodging $56,762 122 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,160 10 payments
  5. Food and Beverage $32,870 470 payments
Products named General payments · program years 2019–2025
  1. HOFFMANN $177,658 51 payments
  2. SALVATION Trauma & Extremities $147,161 137 payments
  3. PROSTEP $64,622 48 payments
  4. SALVATION Foot And Ankle $63,247 61 payments
  5. INFINITY $40,401 6 payments
  6. PROPHECY $37,883 23 payments
  7. ORTHOLOC 2 LAPIFUSE $32,341 14 payments
  8. DYNEX $30,966 23 payments
  9. REDEMPTION $28,748 12 payments
  10. INVISION $27,280 2 payments
  11. Other $274,850 530 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Wright Medical Technology, Inc. $330 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,286

Median for Podiatry: 160

Drug cost

$81,278

Median for Podiatry: $2,368

Branded share of claims

34.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 26 $36,280
Ammonium Lactate Generic 631 $12,530
Ciclopirox Generic 321 $9,332
Ciclopirox Ciclopirox Olamine Brand 474 $6,459
Xarelto Rivaroxaban Brand 22 $5,143
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 107 $2,239
Gentamicin Sulfate Generic 44 $1,892
Diclofenac Sodium Generic 102 $1,348
Clotrimazole Generic 69 $1,288
Cephalexin Generic 65 $748

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$1,048,139

Medicare's payments for the services billed

Medicare patients

183

Average age 73

Services billed

1,558

98 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Arthritis 55%
Depression 50%
Ischemic heart disease 42%
Chronic kidney disease 39%
COPD 31%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record